This Phase 1 open-label study is evaluating the safety of ImmunityBio’s IBRX-042 therapeutic Vaccine in patients with HPV-associated tumors (cervical, esophageal, head, neck, and anal squamous cell carcinomas, as well as vaginal, vulvar, and penile cancers).

Acceptance Requirements

Adult patients diagnosed with histologically confirmed HPV-associated cancer documented as HPV- or p16+ carcinoma.

Must be able to walk, care for themselves and attend study-site visits